Clinicopathological predictors of long-term benefit in breast cancer treated with neoadjuvant chemotherapy | Zendy

Marco Gálvez-Niño | Zendy; Carlos A. Castañeda | Zendy; Joselyn Sanchez | Zendy; Miluska Castillo | Zendy; Lia Pamela Rebaza Vasquez | Zendy; Gabriela Calderón | Zendy; Miguel De la Cruz | Zendy; José M. Cotrina | Zendy; Julio E. Abugattas | Zendy; Jorge Dunstan | Zendy; Henry Miller | Zendy; Ómar Mejìa | Zendy; Henry Gómez | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clinicopathological predictors of long-term benefit in breast cancer treated with neoadjuvant chemotherapy

Author(s) -

Marco Gálvez-Niño,

Carlos A. Castañeda,

Joselyn Sanchez,

Miluska Castillo,

Lia Pamela Rebaza Vasquez,

Gabriela Calderón,

Miguel De la Cruz,

José M. Cotrina,

Julio E. Abugattas,

Jorge Dunstan,

Henry Miller,

Ómar Mejìa,

Henry Gómez

Publication year - 2018

Publication title -

world journal of clinical oncology

Language(s) - English

Resource type - Journals

ISSN - 2218-4333

DOI - 10.5306/wjco.v9.i2.33

Subject(s) - medicine , breast cancer , chemotherapy , tumor infiltrating lymphocytes , biopsy , population , stage (stratigraphy) , oncology , gastroenterology , pathological , pathology , h&e stain , neoadjuvant therapy , cancer , immunohistochemistry , immunotherapy , biology , paleontology , environmental health

To investigate the survival impact of clinicopathological factors, including pathological complete response (pCR) and tumor-infiltrating lymphocytes (sTIL) levels according to subtypes, in breast cancer (BC) patients who received neo-adjuvant chemotherapy (NAC).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research